. 2024 Oct 10;12(10):2050. doi: 10.3390/microorganisms12102050

Table 3.

Results of the Cox proportional hazard models: factors associated with SVR4 and SVR12; HR-hazard ratio; CI-confidence interval; CTD—connective tissue disease; PWID—people who inject drugs.

Model 1	SVR4						SVR12
Variable	Univariante			Multivariate			Univariante			Multivariate
Variable	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Sex	0.919	0.61–1.23	0.401				0.836	0.48–1.21	0.332
Ages	0.951	0.91–0.99	0.003	0.991	0.90–1.04	0.194	0.921	0.89–0.97	0.001	1.014	0.74–1.34	0.849
Stage of liver fibrosis	0.801	0.69–0.97	0.001	0.855	0.68–0.96	0.019	0.884	0.75–0.96	0.002	0.964	0.95–0.99	0.011
Hypertension	0.738	0.45–1.17	0.154				0.742	0.44–1.28	0.151
Other CV diseases	0.575	0.35–1.36	0.224				0.647	0.32–1.27	0.298
Diabetes mellitus	0.861	0.51–1.28	0.234				0.952	0.62–1.85	0.936
Respiratory disease	0.942	0.35–1.43	0.207				0.636	0.41–1.36	0.487
Chronic kidney failure	0.671	0.42–1.73	0.651				0.721	0.49–1.21	0.645
Dialysis	0.669	0.26–1.97	0.501				0.984	0.30–2.08	0.670
Malignant diseases	0.792	0.50–1.37	0.436				0.169	0.40–1.23	0.569
CTD	0.357	0.14–1.18	0.969				0.401	0.12–1.24	0.290
Cryoglobulinemia	0.895	0.01–5.25	0.326				0.811	0.11–5.87	0.598
Epilepsy	1.198	0.36–2.26	0.424				1.236	0.74–2.98	0.657
Hypo/hyperthyroidism	0.893	0.48–1.43	0.845				1.062	0.97–1.83	0.941
Mood disorders	1.158	0.75–1.49	0.360				1.148	0.67–1.58	0.290
Psychoses	0.821	0.40–1.22	0.460				0.911	0.54–1.62	0.215
HIV	0.548	0.40–0.95	0.004	0.758	0.50–1.17	0.187	0.277	0.53–0.99	0.004	0.851	0.60–1.17	0.187
Antiretroviral therapy	1.160	0.62–1.32	0.120				1.760	0.85–2.59	0.120
HBV	0.974	0.78–1.25	0.521				0.622	0.21–2.58	0.240
Resolved HBV	0.929	0.49–1.43	0.309				0.861	0.41–1.74	0.680
Chronic alcoholics	0.479	0.20–1.18	0.525				0.388	0.06–1.25	0.490
PWID	1.870	1.01–1.99	0.002	2.912	0.93–4.80	0.068	1.481	1.10–1.96	0.001	1.297	0.85–1.90	0.174
Model 2	SVR4						SVR12
Variable	Univariante			Multivariate			Univariante			Multivariate
Variable	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Sex	0.919	0.61–1.23	0.401				0.836	0.48–1.21	0.332
Ages	0.951	0.91–0.99	0.003	0.878	0.88–0.95	0.001	0.921	0.89–0.97	0.001	1.089	0.41–1.29	0.950
Stage of liver fibrosis	0.801	0.69–0.97	0.001	0.914	0.80–0.97	0.003	0.884	0.75–0.96	0.002	0.870	0.74–0.98	0.007
HCV RNA quantitative	1.970	1.13–201	0.278				1.118	1.03–1.15	0.281
Hepatitis C genotype	1.541	0.79–2.17	0.731				0.527	0.92–1.12	0.754
Fibrosis-4 index	0.881	0.44–0.98	0.034	0.811	0.71–1.17	0.245	0.745	0.57–1.08	0.041	0.895	0.54–1.59	0.256
Child–Pugh class	1.001	0.30–1.97	0.541				1.035	0.57–1.98	0.857
Degree of fibrosis kPa	2.095	0.91–4.64	0.098	0.979	0.68–1.84	0.167	0.917	0.84–0.98	0.036	0.887	0.75–1.48	0.398
Degree of steatosis bD/m	1.045	0.94–1.42	0.541				1.004	0.99–1.09	0.504
Advanced complications	0.687	0.52–0.77	0.012	0.684	0.39–1.74	0.241	0.428	0.32–0.58	0.020	0.642	0.41–1.18	0.210
Hepatocellular carcinoma	0.556	0.31–1.89	0.314				0.679	0.35–1.29	0.128